title: β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity?
abstract: The capacity of G protein-coupled receptors (GPCRs) to activate multiple G protein isoforms and additional effectors such as β-arrestins has become a well-established paradigm and provides the basis for developing drugs that preferentially activate beneficial signalling pathways. There are many published examples of ligand-directed signalling, and recent studies have provided direct evidence that different agonists stabilise distinct GPCR conformations. This field is rapidly evolving, but a key question is whether signalling bias observed in heterologous cell expression systems can be translated to physiological systems of therapeutic relevance. The paper by Ngala et al. in this issue of the journal addresses the capacity of agonists acting at the β2-adrenoceptor to engender signalling bias in relation to glucose uptake in isolated skeletal muscle, an area of considerable potential interest in targeting insulin-independent pathways for the treatment of type 2 diabetes. The authors show that clenbuterol and BRL37344 have opposite effects on glucose uptake, despite both having agonist actions at β2-adrenoceptors. This study underlines some of the obstacles associated with studies in a complex physiological system but nonetheless highlights the need to consider signalling bias in the relevant target tissue when developing novel drugs.
authors: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 399 Royal Parade, Parkville, Melbourne, VIC, 3052, Australia.
authors: Bronwyn A
authors: BA
authors: Evans
authors: Dana S
authors: DS
authors: Hutchinson
authors: Roger J
authors: RJ
authors: Summers
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000494:pharmacology; D000818:Animals; D005947:Glucose / Q000378:metabolism*; D008024:Ligands; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D008024:Ligands; D018343:Receptors, Adrenergic, beta-2; D005947:Glucose
references: Mol Pharmacol. 2007 Nov;72(5):1359-68
references: 17717109
references: ACS Chem Neurosci. 2012 Mar 21;3(3):193-203
references: 22860188
references: Science. 2012 Mar 2;335(6072):1106-10
references: 22267580
references: J Biol Chem. 2012 Oct 26;287(44):37066-77
references: 22965232
references: Mol Pharmacol. 2009 Jan;75(1):158-65
references: 18838481
references: Mol Pharmacol. 2003 Sep;64(3):679-88
references: 12920204
references: J Pharmacol Exp Ther. 2011 Feb;336(2):296-302
references: 21030484
references: Pharmacol Rev. 2010 Jun;62(2):265-304
references: 20392808
references: Nat Chem Biol. 2012 Jul;8(7):631-8
references: 22634634
references: J Pharmacol Exp Ther. 2010 Dec;335(3):572-9
references: 20801892
references: Mol Pharmacol. 2012 Aug;82(2):291-301
references: 22584219
references: J Biol Chem. 2012 Feb 3;287(6):3617-29
references: 22069312
references: Nat Rev Drug Discov. 2013 Mar;12(3):205-16
references: 23411724
references: Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93
references: 22025698
references: Proc Natl Acad Sci U S A. 2012 May 22;109(21):8304-9
references: 22573814
references: Nat Chem Biol. 2011 Aug 21;7(10):692-700
references: 21857662
references: FASEB J. 2011 Dec;25(12):4486-97
references: 21865315
references: Mol Pharmacol. 2012 Dec;82(6):1174-82
references: 22973061
references: Mol Pharmacol. 2011 Feb;79(2):298-307
references: 20978120
references: Br J Pharmacol. 2008 Oct;155(3):395-406
references: 18552870
references: Br J Pharmacol. 2009 Dec;158(7):1676-82
references: 19912225
references: Mol Pharmacol. 2011 Sep;80(3):367-77
references: 21610196
references: Mol Pharmacol. 2008 Nov;74(5):1417-28
references: 18684840
references: J Pharmacol Exp Ther. 2013 Mar;344(3):708-17
references: 23300227
references: Mol Pharmacol. 2011 Mar;79(3):575-85
references: 21163968
references: Methods Enzymol. 2013;522:229-62
references: 23374189
references: Naunyn Schmiedebergs Arch Pharmacol. 2013 Sep;386(9):761-73
references: 23564017
references: J Neurosci. 2010 Dec 8;30(49):16459-68
references: 21147985
references: Mol Pharmacol. 2008 Jul;74(1):162-72
references: 18403719
references: Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5211-6
references: 23479653
references: Br J Pharmacol. 2010 Mar;159(5):1022-38
references: 20132209
references: J Pharmacol Exp Ther. 2012 Jun;341(3):820-8
references: 22438472
references: Br J Pharmacol. 2010 Jul;160(5):1048-61
references: 20590599
references: Expert Opin Drug Discov. 2011 Aug;6(8):811-25
references: 22651124